REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
9.32
-0.18 (-1.89%)
At close: Sep 1, 2026, 4:00 PM EDT
9.41
+0.09 (0.97%)
After-hours: Sep 1, 2026, 7:30 PM EDT
REGENXBIO Revenue
REGENXBIO had revenue of $108.02M in the quarter ending June 30, 2026, with 405.73% growth. This brings the company's revenue in the last twelve months to $174.48M, up 12.00% year-over-year. In the year 2025, REGENXBIO had annual revenue of $170.44M with 104.54% growth.
Revenue (ttm)
$174.48M
Revenue Growth
+12.00%
P/S Ratio
3.53
Revenue / Employee
$470,302
Employees
371
Market Cap
615.24M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 170.44M | 87.11M | 104.54% |
| Dec 31, 2024 | 83.33M | -6.91M | -7.66% |
| Dec 31, 2023 | 90.24M | -22.48M | -19.94% |
| Dec 31, 2022 | 112.72M | -357.62M | -76.03% |
| Dec 31, 2021 | 470.35M | 315.78M | 204.30% |
| Dec 31, 2020 | 154.57M | 119.33M | 338.70% |
| Dec 31, 2019 | 35.23M | -183.27M | -83.88% |
| Dec 31, 2018 | 218.51M | 208.11M | 2,002.42% |
| Dec 31, 2017 | 10.39M | 5.80M | 126.48% |
| Dec 31, 2016 | 4.59M | -3.00M | -39.52% |
| Dec 31, 2015 | 7.59M | 1.47M | 23.99% |
| Dec 31, 2014 | 6.12M | 33.00K | 0.54% |
| Dec 31, 2013 | 6.09M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| CorMedix | 462.25M |
| Arvinas | 316.70M |
| Autolus Therapeutics | 117.39M |
| ARS Pharmaceuticals | 116.93M |
| Verastem | 87.53M |
| OmniAb | 38.46M |
| Prime Medicine | 4.07M |
| Altimmune | 31.00K |
RGNX News
- 7 days ago - Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of REGENXBIO Inc. (RGNX) - Business Wire
- 7 days ago - Regenxbio price target lowered to $21 from $23 at H.C. Wainwright - TheFly
- 7 days ago - REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli - PRNewsWire
- 7 days ago - Regenxbio price target lowered to $29 from $32 at Baird - TheFly
- 7 days ago - Regenxbio price target lowered to $32 from $45 at Clear Street - TheFly
- 8 days ago - RGNX Investor Notice: Johnson Fistel Investigates REGENXBIO Inc. Following Clinical Hold - GlobeNewsWire
- 8 days ago - BofA says Regenxbio’s MPS setback ‘disappointing,’ larger catalysts intact - TheFly
- 8 days ago - Morning Movers: Regenxbio sinks following clinical hold on RGX-121 - TheFly